开放与机器人经食管裂孔食管切除术的生活质量相似
单中心回顾性研究纳入2013至2018年临床I至III期食管癌行胃管重建的309例患者(开放经食管裂孔212例、机器人经食管裂孔97例),比较围手术期结果及术前至术后12个月的生活质量与复发恐惧。机器人组淋巴结清扫数更多、住院更短、术后肠梗阻更少、出院阿片类处方更少,但调整后两组生活质量量表与复发恐惧评分至术后1年无显著差异。
要点
- 机器人经食管裂孔入路围手术期获益明确,但未带来患者报告的生活质量优势
- 两组QLQ-C30、QLQ-OES18及复发恐惧评分至术后1年无显著差异
- 机器人组淋巴结清扫更多、住院更短、术后肠梗阻与出院阿片处方更少
核心结论
- 机器人经食管裂孔食管切除术相较开放经食管裂孔手术未显示明确的患者报告获益,但具有多项围手术期优势。
研究设计与样本
- 单中心、高手术量学术中心2013至2018年临床I至III期食管癌行胃管重建患者,共309例(开放经食管裂孔212例,机器人经食管裂孔97例),术前及术后1、6、12个月行EORTC QLQ-C30、QLQ-OES18与复发恐惧问卷调查,采用线性混合效应模型比较评分并比较围手术期结果。
主要发现
- 机器人组淋巴结清扫数14±0.8枚 vs 开放组11.2±0.4枚(P=.01),住院10.0±6.7天 vs 12.1±7.0天(P=.03)。
- 机器人组术后肠梗阻发生率5% vs 15%(P=.02),出院时阿片类处方71% vs 85%(P=.03)。
- 调整后两组QLQ-C30、QLQ-OES18及复发恐惧评分至术后1年无显著差异。
临床怎么用
- 机器人经食管裂孔食管切除术可凭借淋巴结清扫更充分、住院更短及术后肠梗阻更少等围手术期优势用于食管癌外科,但不应以改善生活质量作为选择依据。
局限性
- 单中心高手术量学术中心回顾性设计,非随机分组,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patient-reported outcomes (PROs) for minimally invasive esophagectomy (MIE) have demonstrated benefits compared with open transthoracic or 3-hole esophagectomy. PROs, including quality of life (QoL) and fear of recurrence (FoR), comparing open transhiatal esophagectomy (THE) and transhiatal robotic-assisted MIE (Th-RAMIE) have been limited. METHODS: At a single, high-volume academic center, patients undergoing THE and Th-RAMIE with gastric conduit for clinical stage I to III esophageal cancer from 2013 to 2018 were evaluated. The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30), the EORTC Quality of Life Questionnaire in Esophageal Cancer (QLQ-OES18), and the FoR survey were administered preoperatively and at 1, 6, and 12 months postoperatively. Linear mixed-effects models were used for QoL and FoR score comparisons. Perioperative outcomes were also compared. RESULTS: A total of 309 patients (212 in the group and 97 in the Th-RAMIE group) were included. The Th-RAMIE cohort had a significantly higher number of lymph nodes harvested (14 ± 0.8 vs 11.2 ± 0.4; P = .01), a shorter length of stay (days, 10.0 ± 6.7 vs 12.1 ± 7.0; P = .03), lower rates of postoperative ileus (5% vs 15%; P = .02), and fewer opioids prescribed at discharge (71% vs 85%; P = .03). After adjustment, there were no significant differences in QLQ-C30, QLQ-OES18, and FoR scores between the groups out to 1 year postoperatively. CONCLUSIONS: There were no clear patient-reported benefits of Th-RAMIE over THE for esophageal cancer. However, Th-RAMIE conferred several perioperative benefits.
引用
- Williams AM, Kathawate RG, Zhao L, et al. Similar Quality of Life After Conventional and Robotic Transhiatal Esophagectomy. Ann Thorac Surg. 2021. PMID: 33745901. doi:10.1016/j.athoracsur.2021.03.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。